Insurance Coverage for erectile dysfunction drugs

Clinical Pharmacology and Therapeutics

Volumn 89, Issue 1, 2011, Pages 19-21

  Hornbrook, M C ^a   Holup, J ^a  

^a CENTER FOR HEALTH RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SILDENAFIL;

COST EFFECTIVENESS ANALYSIS; DRUG COST; ERECTILE DYSFUNCTION; HEALTH CARE COST; HEALTH CARE ORGANIZATION; HEALTH INSURANCE; HUMAN; IMPOTENCE; MEDICAID; MEDICARE; PRESCRIPTION; PRIORITY JOURNAL; QUALITY OF LIFE; REIMBURSEMENT; REVIEW; SEXUAL FUNCTION;

ERECTILE DYSFUNCTION; HEALTH POLICY; HUMANS; INSURANCE COVERAGE; INSURANCE, PHARMACEUTICAL SERVICES; MALE; MORALS; NATIONAL HEALTH INSURANCE, UNITED STATES; PHOSPHODIESTERASE 5 INHIBITORS; PREVALENCE; UNITED STATES;

EID: 78650439465     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2010.265     Document Type: Review

References (10)

1. Lexchin, J. Bigger and better: how Pfizer redefined erectile dysfunction. PLoS Med. 3, E132 (2006).
2. Klein, R. & Sturm, H. Viagra: a success story for rationing? Health Aff. (Millwood) 21, 177-187 (2002).
3. Sun, P., Seftel, A., Swindle, R., Ye, W. & Pohl, G. The costs of caring for erectile dysfunction in a managed care setting: evidence from a large national claims database. J. Urol. 174, 1948-1952 (2005).
4. Titlow, K., Randel, L., Clancy, C.M., & Emanuel, E.J. Drug coverage decisions: the role of dollars and values. Health Aff. (Millwood) 19, 240-247 (2000).
5. Feldman, H.A., Goldstein, I., Hatzichristou, D.G., Krane, R.J. & McKinlay, J.B. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J. Urol. 151, 54-61 (1994).
6. Cooke, C.E., Wong, W. & Lee, H. Utilization and cost of sildenafil in a large managed care organization with a quantity limit on sildenafil. J. Manag. Care Pharm. 11, 674-680 (2005).
7. Manson, H. The role of the "lifestyle" label and negative bias in the allocation of health resources for erectile dysfunction drugs: an ethics-based appraisal. Int. J. Impot. Res. 18, 98-103 (2006).
8. Giacomini, M. One of these things is not like the others: the idea of precedence in health technology assessment and coverage decisions. Milbank Q. 83, 193-223 (2005).
9. Smith, K.J. & Roberts, M.S. The cost-effectiveness of sildenafil. Ann. Intern. Med. 132, 933-937 (2000).
10. Sabin, J.E. & Daniels, N. Determining "medical necessity" in mental health practice. Hastings Cent. Rep. 24, 5-13 (1994).